Oxford Endovascular

Oxford Endovascular Ltd (OE) is a medical device company spinout of Oxford University. The company is developing a unique next generation flow-diverter, OXIFLOW™ for the minimally invasive treatment of intracranial aneurysms preventing death or disability due to brain haemorrhage.

The Endovascular Cerebral Aneurysms Repair (ECAR) market is estimated to reach $3 billion by 2027 and is growing at around 20% CAGR.

Over the next five years, flow-diverters are expected to grow rapidly and, with an improved technology, expand usage to become a first-line treatment accounting for up to 40% of the ECAR market by the end of 2035. The flow-diverter market itself is currently $250m expected to become a $1 billion market opportunity over the next 10 years. Exit valuations have been seen up to $540m due to the rapid market growth and high margins to be made by acquirers.